Focused On-demand Library for 26S proteasome regulatory subunit 8

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P62195

UPID:

PRS8_HUMAN

Alternative names:

26S proteasome AAA-ATPase subunit RPT6; Proteasome 26S subunit ATPase 5; Proteasome subunit p45; Thyroid hormone receptor-interacting protein 1; p45/SUG

Alternative UPACC:

P62195; A8K3Z3; A8K763; O35051; O43208; P47210; P52915; P52916

Background:

The 26S proteasome regulatory subunit 8, known as PSMC5, is a crucial component of the 26S proteasome. This multiprotein complex is essential for the ATP-dependent degradation of ubiquitinated proteins, playing a pivotal role in maintaining protein homeostasis. By eliminating misfolded or damaged proteins and those no longer needed, the proteasome ensures cellular functions are not impaired. PSMC5 is part of the AAA (ATPases associated with diverse cellular activities) protein ring, responsible for unfolding and translocating target proteins into a proteolytic chamber for degradation.

Therapeutic significance:

Understanding the role of 26S proteasome regulatory subunit 8 could open doors to potential therapeutic strategies.